3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Triple Negative Breast Neoplasms
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Interventions
exemestane
2
Letrozole
2
seviteronel
1
sargramostim
1
ribociclib
1
methyl N-acetylsibirosaminide
1
elacestrant
1
Trastuzumab
1
Tamoxifen
1
Suspensions
1
Receptor Protein-Tyrosine Kinases
1
Presenilin-1
1
Pemetrexed
1
Leuprolide
1
Injections
1
HER2 peptide (369-377)
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Goserelin
1
Fentanyl
1
Anastrozole
1
90Y-octreotide, DOTA-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Breast Neoplasms, Male
×
seviteronel
×
Clear all
NCT02580448
2019-02-01
CLARITY-01
Innocrin Pharmaceutical
Phase 1/2
Completed
175 enrolled